Citations

Clear

125 citation(s) found for "Tyson, MD".

Nonsurgical Management of Combined Occipitocervical and Atlantoaxial Distraction Injuries
Kolz, Joshua M. , Christensen, Tyson C. , Diehn, Felix E. , Sebastian, Arjun S. , Currier, Bradford L. , Nassr, Ahmad , Currier, Bradford , Nassr, Ahmad N , Diehn, Felix E

Mayo Clinic

JBJS Case Connector | January 14, 2021 | Volume: 11 | Issue: 1 | Pages: e20.00228-e20.00228

10.2106/jbjs.cc.20.00228 | PMID 33502138 Get It

Case: A 41-year-old man sustained occipitocervical dislocation (OCD) and atlantoaxial dislocation (AAD) injuries in a motor vehicle collision. These injuries were treated nonoperatively with a hard cervical collar and activity restrictions with an excellent result at 4-year follow-up. Conclusion: OCD and AAD injuries require prompt diagnosis and immobilization. Standard of care for coexisting injuries is occipitocervical fusion; however, some patients have coexisting injuries which may prevent operative treatment. These polytrauma patients require a creative nonoperative approach with close follow-up to avoid neurologic decline.
Variation in Lymph Node Yield After Radical Cystectomy
Faraj, Kassem , Judge, Nathanael, Blodgett, Gail, Stanton, Melissa, Tyson, Mark D. , Faraj, Kassem S , Stanton, Melissa L, Chang, Yu‐Hui

Mayo Clinic

American Journal of Clinical Pathology | October 29, 2020 | Volume: 156 | Issue: 3 | Pages: 391-398

10.1093/ajcp/aqaa247 | PMID 33608695 Get It

Abstract Objectives To test the hypothesis that lymph node yield will vary by pathology assistant (PA) in patients undergoing radical cystectomy (RC) with pelvic lymph node dissection (PLND). Methods This is a single-institution retrospective review that included patients who underwent an RC with PLND for bladder cancer from January 1, 2007, to January 1, 2018. Predicted mean lymph node counts were generated using multivariable regression analysis. Results In a total of 430 patients who underwent RC with PLND, the median lymph node count (interquartile range) was 15.0 (11.0-21.0). The frequency of the limits of lymphadenectomy was as follows: external iliac, internal iliac, and obturator (true pelvis) (33.3%); true pelvis plus common iliac to the level of the aortic bifurcation (47.9%); and inferior mesenteric artery (18.8%). On descriptive analysis, there were differences in lymph node yield when evaluating the following variables: level of dissection, clinical stage, neoadjuvant chemotherapy, surgical approach, surgeon, pathologist, and PA (P < .05). On multivariable analysis, adjusted lymph node counts varied between surgeons, pathologists, clinical stage, and level of dissection but not by PA (P = .18). Conclusions Lymph node yield after RC varies on several known levels, including surgeon, extent of lymphadenectomy, clinical stage, and pathologist. This study found no significant variation in lymph node yield according to PA.
Editorial Comment
Tyson, Mark D.

Mayo Clinic

Journal of Urology | July 27, 2020 | Volume: 204 | Issue: 4 | Pages: 724-725

10.1097/ju.0000000000001089.01 | PMID 32716246 Get It

The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction
Himes, Benjamin , Peterson, Timothy E., Mooij, Tristan de, Garcia, Luz Milbeth Cumba, Uhm, Sarah , Yan, David Z., Tyson, Jasmine , Jin‐Lee, Helen J. , Parney, Daniel, Abukhadra, Yasmina, Gustafson, Michael P. , Dietz, Allan B. , Johnson, Aaron J. , Maus, Rachel L.G., Himes, Benjamin T., de Mooij, Tristan, Garcia, Luz M Cumba, Jung, Mi-Yeon, Yan, David, Jin-Lee, Helen J, Maus, Rachel L, Dietz, Allan B , Himes, Benjamin T , Jung, Mi-Yeon, Johnson, Aaron J. , Dong, Haidong , Markovic, Svetomir N. , Lucien, Fabrice , Parney, Ian F.

Mayo Clinic

Neuro-Oncology | February 19, 2020 | Volume: 22 | Issue: 7 | Pages: 967-978

10.1093/neuonc/noaa029 | PMID 32080744 Get It

Abstract Background Immunosuppression in glioblastoma (GBM) is an obstacle to effective immunotherapy. GBM-derived immunosuppressive monocytes are central to this. Programmed cell death ligand 1 (PD-L1) is an immune checkpoint molecule, expressed by GBM cells and GBM extracellular vesicles (EVs). We sought to determine the role of EV-associated PD-L1 in the formation of immunosuppressive monocytes. Methods Monocytes collected from healthy donors were conditioned with GBM-derived EVs to induce the formation of immunosuppressive monocytes, which were quantified via flow cytometry. Donor-matched T cells were subsequently co-cultured with EV-conditioned monocytes in order to assess effects on T-cell proliferation. PD-L1 constitutive overexpression or short hairpin RNA–mediated knockdown was used to determined the role of altered PD-L1 expression. Results GBM EVs interact with both T cells and monocytes but do not directly inhibit T-cell activation. However, GBM EVs induce immunosuppressive monocytes, including myeloid-derived suppressor cells (MDSCs) and nonclassical monocytes (NCMs). MDSCs and NCMs inhibit T-cell proliferation in vitro and are found within GBM in situ. EV PD-L1 expression induces NCMs but not MDSCs, and does not affect EV-conditioned monocytes T-cell inhibition. Conclusion These findings indicate that GBM EV-mediated immunosuppression occurs through induction of immunosuppressive monocytes rather than direct T-cell inhibition and that, while PD-L1 expression is important for the induction of specific immunosuppressive monocyte populations, immunosuppressive signaling mechanisms through EVs are complex and not limited to PD-L1.
GEMINI: An open-label, single-arm, phase II trial of intraoperative gemcitabine intravesical instillation in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma.
Leibovich, Bradley C. , Thompson, R. Houston, Potretzke, Aaron M. , Chow, George K. , Tollefson, Matthew K. , Schulte, Phillip J. , Tyson, Mark D. , Boorjian, Stephen A. , Packiam, Vignesh T. , Lyon, Timothy D.

Mayo Clinic

Journal of Clinical Oncology | February 19, 2020 | Volume: 38 | Issue: 6_suppl | Pages: TPS594-TPS594

10.1200/jco.2020.38.6_suppl.tps594 Get It

TPS594 Background: The standard treatment for upper tract urothelial carcinoma (UTUC) is radical nephroureterectomy (RNU) with bladder cuff resection. Subsequent intravesical recurrence is common and results in patient morbidity and increased healthcare cost. Level 1 evidence has demonstrated reduction of intravesical recurrence with instillation of intravesical Mitomycin C at 10 days following RNU. However, there has been limited adoption of Mitomycin C due to concerns for toxicity and logistics of postoperative drug delivery. Meanwhile, immediate intravesical gemcitabine has been shown to reduce intravesical recurrence following transurethral resection of bladder cancers without increasing toxicity compared to placebo. Moreover, small series have suggested improved efficacy of intraoperative intravesical chemotherapy for RNU. The purpose of the GEMINI trial, therefore, is to prospectively establish the safety and efficacy of intraoperative instillation of intravesical gemcitabine in patients undergoing RNU for UTUC. Methods: GEMINI is a multi-center open-label, single-arm, Phase II study that aims to enroll 90 patients with cTa-T4N0M0 UTUC. Patients receive intraoperative intravesical instillation of gemcitabine at the beginning of RNU, to be held in the bladder for at least 1 hour. The instilled drug will be drained prior to resection of the bladder cuff. Patients will undergo standard of care postoperative surveillance, including cystoscopy at 3, 6, 12, 18, and 24 months. The primary endpoint is 1-year intravesical recurrence-free survival. The historical event rate for no treatment is 30%, and we estimated a 40% relative reduction in event rate with gemcitabine. The study is powered to provide 80% power to detect this difference based on a one-sided exact test of proportions with alpha level 0.05. Secondary endpoints include time to recurrence and stratification of recurrence free survival by tumor grade, tumor stage, neoadjuvant chemotherapy, ureteral tumor location, and history of bladder cancer. Safety and adverse event endpoints will be evaluated. Complete accrual is expected within 3 years.
IMMU-36. THE ROLE OF PD-L1 IN GLIOBLASTOMA-DERIVED EXTRACELLULAR VESICLES IN THE INDUCTION OF IMMUNOSUPPRESSIVE MONOCYTES
Peterson, Timothy E., Tyson, Jasmine , Lee, Helen , deMooij, Tristan, Cumba-Garcia, Luz, Jung, M. Katherine , Gustafson, Michael P. , Johnson, Aaron , Maus, Rachel L.G., Markovic, Svetomir, Lucien-Matteoni, Fabrice, Yan, David Z., Uhm, Sarah , Abukhadra, Mina, Parney, Daniel, Himes, Benjamin , Dietz, Allan B. , Dong, Haidong , Parney, Ian F.

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi126-vi127

10.1093/neuonc/noz175.528 Get It

Abstract Glioblastoma (GBM) is the most common and lethal primary brain tumor, and novel therapeutic strategies that make a substantial impact on outcomes are sorely needed. Immunotherapies have shown great promise in the treatment of a number of cancers in recent year, and a concerted effort is being made to apply these treatment paradigms to GBM. However, many GBM patients exhibit profound immunosuppression, likely limiting the efficacy of such approaches. The mechanisms of this immunosuppression are poorly understood, but tumor-derived extracellular vesicles (EVs), may play a role. We demonstrate that GBM-derived EVs induce the development of myeloid-derived suppressor cells (MDSCs) and non-classical monocytes (NCMs). We further demonstrate that these EV-induced monocytic cells are immunosuppressive, resulting in impaired T cell proliferation upon co-culture. We found that the immunosuppressive effects of tumor-derived EVs appear to be driven by the induction of these immunosuppressive monocytes, as EV treatment of T cells did not significantly impact T cell proliferation. Further, we sought to characterize the important of programmed death ligand 1 (PD-L1) in the induction of these immunosuppressive monocyte populations. We found PD-L1 to be expressed in the EVs from GBM cell lines, and that modulation in PD-L1 expression via either constitutive overexpression or shRNA-mediated knockdown resulted in concordant changes in expression in tumor-derived EVs. We demonstrate that PD-L1 is important for the induction of NCM but not for MDSCs. Taken together, these findings point to a significant role for tumor-derived EVs in the induction of immunosuppressive monocytes in GBM, and that these cells may be a driving force of systemic immunosuppression. PD-L1 is one factor expressed in EVs that has immunomodulatory properties, but additional EV cargo likely plays a major role in the induction of immunosuppressive cells.
Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis
Chandrasekar, Thenappan , Klotz, Laurence , Emberton, Mark , Haider, Masoom A. , Taneja, Samir S. , Fleshner, Neil , Finelli, Antonio , Perlis, Nathan , Tyson, Mark D. , Klaassen, Zachary , Arora, Karan, Goldberg, Hanan , Ahmad, Ardalan E. , Arora, Karan , Wallis, Christopher J D

Mayo Clinic

Journal of Urology | October 14, 2019 | Volume: 203 | Issue: 6 | Pages: 1085-1093

10.1097/ju.0000000000000595 | PMID 31609177 Get It

Methods for the Watch the Spot Trial. A Pragmatic Trial of More- versus Less-Intensive Strategies for Active Surveillance of Small Pulmonary Nodules
Gould, Michael K. , Kelly, Karen , Altman, Danielle, Bie, Evan de, Dyer, Debra S. , Barbosa, Eduardo J. Mortani , Qi, Lihong , Vaszar, Laszlo T. , Yu, Sophronia , Miglioretti, Diana L. , Miglioretti, Diana L , Kelly, Karen , Smith‐Bindman, Rebecca , Barjaktarević, Igor , Creekmur, Beth , Mularski, Richard A.

Mayo Clinic

Annals of the American Thoracic Society | July 17, 2019 | Volume: 16 | Issue: 12 | Pages: 1567-1576

10.1513/annalsats.201903-268sd | PMID 31314549 Get It

Abstract Small pulmonary nodules are most often managed by surveillance imaging with computed tomography (CT) of the chest, but the optimal frequency and duration of surveillance are unknown. The Watch the Spot Trial is a multicenter, pragmatic, comparative-effectiveness trial with cluster randomization by hospital or health system that compares more- versus less-intensive strategies for active surveillance of small pulmonary nodules. The study plans to enroll approximately 35,200 patients with a small pulmonary nodule that is newly detected on chest CT imaging, either incidentally or by screening. Study protocols for more- and less-intensive surveillance were adapted from published guidelines. The primary outcome is the percentage of cancerous nodules that progress beyond American Joint Committee on Cancer seventh edition stage T1a. Secondary outcomes include patient-reported anxiety and emotional distress, nodule-related health care use, radiation exposure, and adherence with the assigned surveillance protocol. Distinctive aspects of the trial include: 1) the pragmatic integration of study procedures into existing clinical workflow; 2) the use of cluster randomization by hospital or health system; 3) the implementation and evaluation of a system-level intervention for protocol-based care; 4) the use of highly efficient, technology-enabled methods to identify and (passively) enroll participants; 5) reliance on data collected as part of routine clinical care, including data from electronic health records and state cancer registries; 6) linkage with state cancer registries for complete ascertainment of the primary study outcome; and 7) intensive engagement with a diverse group of patient and nonpatient stakeholders in the design and execution of the study.
Assessment of treatment patterns of nonmuscle invasive bladder cancer patients in privately insured patients.
Tyson, Mark D. , Guo, Amy , Papademetriou, Eros , Spigelman, Samuel, Rotter, David , Potluri, Ravi C.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e16012-e16012

10.1200/jco.2019.37.15_suppl.e16012 Get It

e16012 Background: 75–85% of bladder cancer patients present with non-muscle invasive disease (NMIBC). While transurethral resection of bladder tumors (TURBT) is the initial standard treatment for visible lesions, there is variation in the utilization of adjuvant intravesical treatments in the real world. This study aims to assess current treatment patterns in privately insured NMIBC patients. Methods: Bladder cancer patients were identified from Truven MarketScan Commercial and Medicare Supplemental databases using ICD-9/ICD-10 codes. In the absence of tumor staging information, patients were considered to have NMIBC based on diagnosis of CIS or an algorithm centered on the use of TURBT, intravesical treatments and absence of immediate progression to muscle invasive disease. Patients were included in the final cohort if they had one year of continuous insurance coverage prior to index diagnosis, and were without any bladder cancer treatment during this period. Results: 18,683 patients met the eligibility criteria and had a median follow-up of 23 months; the mean age was 68.6 years and 75% were male. The median time from diagnosis to TURBT was 8 days. 54% of the cohort had an intravesical treatment (35% specifically with Bacillus Calmette–Guérin (BCG), with median time from TURBT of 69 days). 77% of BCG-treated patients received 5 or more administrations during induction. However, only 22% of patients received maintenance BCG after induction. 16% of the total cohort developed a recurrence or progression during the available follow-up; five percent underwent a cystectomy, while seven percent were diagnosed with metastatic disease. Only 4% of patients with 5 or more BCG administrations during induction met the definition for being BCG-unresponsive; this is influenced by the low adherence to BCG maintenance protocol. Conclusions: Only a third of NMIBC patients are given intravesical BCG treatment. Adherence to BCG maintenance protocols is suboptimal. Rates of cystectomy/ exenteration are low, suggesting patients’ preference of bladder preservation and the unmet need for new bladder-sparing alternatives.